Physician profile
Robert S Pinke
NPI 1437155041
$3,544.31
in general payments reported to CMS, 2019-2025
23 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $106 · 2021: $393 · 2022: $265 · 2023: $593 · 2024: $642 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,069.13 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Glaukos Corporation | $643.51 | 2023-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Abbvie INC. | $321.38 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $246.02 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $170.49 | 2024-2025 | Vevye, Triesence, Iheezo |
| Allergan, INC. | $156.61 | 2019-2021 | |
| Sight Sciences, INC. | $144.61 | 2019 | |
| Bausch & Lomb Americas INC. | $143.54 | 2022-2023 | Miebo, Vyzulta, Lotemax Sm |
| Amgen INC. | $118.39 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $89.60 | 2021-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $57.01 | 2019-2022 | |
| Horizon Therapeutics Plc | $56.84 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $45.85 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $44.78 | 2022-2023 | Tobradex St |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.95 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $38.97 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $38.85 | 2019-2022 | |
| Oyster Point Pharma, INC. | $29.21 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $18.89 | 2025 | Syfovre |
| Dompe US, INC. | $18.57 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $15.70 | 2019 | |
| Omeros Corporation | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pinke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.